All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
In January 2017, the European Society of Medical Oncology (ESMO) issued an update of their Clinical Practice Guidelines for Multiple Myeloma (MM), which was published in the March edition of Annals of Oncology. This document built on the previous draft published in 2013. These guidelines comprise comprehensive recommendations covering diagnosis, staging and risk assessment, treatment and response evaluation, and follow-up, and now also include recommendations for supportive care. Since 2013 many advances have been made in all of these areas and therefore a re-evaluation of the previous guidelines was required.
In summary, the updated guidelines build on the significant advances made in drug combination regimens for all classes of MM patient (transplant-eligible, transplant-ineligible and elderly) and include additional guidelines for supportive care. The goal of personalized medicine has still not been reached, but with the R-ISS and advances in cytogenetics, this may be on the horizon sooner rather than later.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox